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Antimuscarinic agents are the first-line choice for the treatment of neurogenic detrusor overactivity 
(NDO). The currently available antimuscarinic drugs have been widely studied in patients presenting 
idiopathic detrusor overactivity; however, investigations evaluating the effects of these drugs on NDO 
are scant, particularly with regard to cost-effectiveness analyses. A pharmacoeconomic evaluation 
was performed to compare the costs and effectiveness of oxybutynin and tolterodine in two different 
formulations, extended (ER) and immediate-release (IR), for the treatment of NDO (based on Brazilian 
maximal consumer price index). A systematic review of literature was conducted in order to obtain 
significant clinical and urodynamic data (based on expert opinion), concerning the effects of these 
drugs in the neurogenic population. Furthermore, a pharmacoeconomic evaluation was performed and 
costs involved were calculated based on percentage effectiveness obtained for the timeframes of one 
month and of one year. The best cost-effectiveness ratio (CER) was observed with oxybutynin IR for the 
urodynamic parameters. In terms of clinical parameters, oxybutynin IR and ER showed the best CER. 
Based on the key urological parameters analyzed, oxybutynin IR was considered the most cost-effective 
antimuscarinic agent.
Uniterms: Urinary Bladder Neurogenic. Muscarinic Antagonists. Pharmaceutical economy.
A terapia antimuscarínica é vista como primeira escolha para o tratamento da hiperatividade detrusora 
de origem neurológica (HDON). No entanto, a maioria dos antimuscarínicos existentes é amplamente 
estudada em pacientes portadores de hiperatividade detrusora idiopática. Assim, existe escassez de 
pesquisas que avaliam esses fármacos na problemática da HDON, principalmente em termos de estudos 
de custo-efetividade. Diante isso, um estudo farmacoeconômico foi realizado (baseado no índice de preço 
máximo ao consumidor) para comparar os custos e a efetividade da oxibutinina e da tolterodina, em 
duas diferentes formulações, cápsulas de liberação imediata (LI) e controlada (LC), para o tratamento 
da HDON. Uma revisão sistemática da literatura foi conduzida para obtenção de dados urodinâmicos e 
clínicos relevantes (baseado em opinião de especialistas), quanto aos efeitos desses fármacos em pacientes 
com distúrbios urológicos de origem neurológica. Após essa etapa, um estudo farmacoeconômico foi 
conduzido e os custos envolvidos foram calculados sobre cada percentual de efetividade obtido, num 
horizonte temporal de 1 mês e 1 ano. A melhor razão de custo-efetividade (RCE) quanto aos parâmetros 
urodinâmicos foi obtida com uso de oxibutinina LI. Quantos aos parâmetros clínicos, oxibutinina LI e 
LC tiveram as melhores RCE. Baseando-se nos principais parâmetros urológicos analisados, oxibutinina 
LI foi considerada o antimuscarínico mais custo-efetivo.
Unitermos: Bexiga urinária neurogênica. Antagonistas muscarínicos. Economia Farmacêutica.
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INTRODUCTION
Neurogenic detrusor overactivity (NDO) is related 
to neurogenic bladder (NB) and generally associated to 
traumatic medullary damage or neurological disease. NB 
can stem from damage above the medulla level such as 
in strokes, tumors and dementia or may be secondary to 
spinal cord medulla lesions such as in cases of traumatic 
spinal cord injury, multiple sclerosis, intervertebral disc 
herniation and inflammatory lesions affecting sites of 
micturition control (Tanagho, Bella, Lue, 2010).
The term NDO refers to neurological damage caused 
by trauma or disease which interferes directly with mictu-
rition. Affected patients present with urinary incontinence, 
urgency incontinence, frequency, residual urine or urinary 
retention. If not treated effectively, patients with NB can 
develop upper urinary tract infections which can be recur-
rent and lead to renal failure. Another aggravating problem 
of NB is its negative impact on patients’ quality of life, 
leading to low self-esteem, and loss of independence, 
particularly among the elderly population (Chancellor, 
Anderson, Boone, 2006).
Neurophysiology of micturition is associated with 
a complex of autonomic and somatic nervous system in-
nervations, which can be divided into afferent and efferent 
pathways. Afferent paths are composed of receptors origi-
nating in the muscle wall and the mucosa of the detrusor 
muscle, where the signal originates. These signals travel 
to the dorsal ganglions and the sacral medulla. The pontine 
center for micturition is the final site where the afferent 
signals are perceived sensorially. The efferent system for 
micturition emerges from the pontine center causing exci-
tation via the sacral parasympathetic pathways to contract 
the detrusor and the sacral somatic pathways to relax the 
sphincter. Other organs are also involved in micturition 
control including the cerebellum, cerebral cortex, thalamus 
and hypothalamus, which exert control over the pontine 
micturition center (Kennelly, DeVoe, 2008).
Conservative therapy with antimuscarinic drugs 
is the first choice for treatment of patients with NDO. 
Two of the leading antimuscarinic drugs available in the 
market are Oxybutynin and Tolterodine which, as anti-
muscarinic agents, have a direct antispasmodic effect on 
smooth muscle receptors. Thus, these drugs inhibit the 
muscarinic action of acetylcholine (released from the 
parasympathetic terminals) on the smooth muscle of the 
detrusor (Woodward, 2004).
Oxybutynin was the first antimuscarinic drug to be 
approved for the management of detrusor overactivity 
secondary to neurogenic bladder. It was developed by Ma-
jewski and patented in 1965. Ten years later (1975), it was 
approved by the Food and Drug Administration (FDA) of 
the United States for treatment of uncontrolled neurogenic 
bladder reflexes as well as for treatment of nocturnal en-
uresis in patients over five years of age. This advance was 
possible due to the fact that the first trials of the main active 
ingredient were conducted using cystometrography in a 
patient with NB, a urodynamic technique which allowed 
the measurement of internal urinary bladder pressure.
In 1980, oxybutynin was shown to be effective not 
only for individuals with NB but also for patients who had 
idiopathic detrusor overactivity or of unknown etiology. 
Mosley et al (1980) carried out a randomized double blind 
study with oxybutynin in 30 patients who had bladder 
instability, whose results showed a subjective improve-
ment in symptoms. This led to the approval in 1992 of 
Oxybutynin by the FDA for detrusor instability (Dionne, 
Ingber, 2006).
A major drawback of oxybutynin use is the high 
level of side effects. The low selectivity in specific 
muscarinic receptors of urinary function, affects other 
physiological systems causing dry mouth, constipation 
and heat intolerance in around one third of patients. These 
side effects are the main reason for noncompliance with 
therapy. Another reason for non-adherence to therapy is the 
need for a three times daily dose. A sustained or extended 
release oxybutynin preparation was developed in order to 
overcome these issues (Aslan, Kogan, 2002). Although 
oxybutynin has collateral effects (particularly immediate 
release form), it remains the most commonly used drug 
in Brazil due to its efficacy and low cost (Palma, 2007).
Another antimuscarinic drug developed in the mid-
1990s was tolterodine, acclaimed as a muscarinic antago-
nist which was more selective for bladder receptors. Over-
all, this medication was better accepted and tolerated by 
patients in comparison to oxybutynin (Woodward, 2004).
Nevertheless, in the Brazilian context, the costs 
involved in treatment with tolterodine for NDO are much 
higher than those with the use of oxybutynin, especially 
considering the price made available by the National 
Agency of Health Safety (ANVISA). The literature rein-
forces the fact that, while the monthly cost of tolterodine 
is higher, it is better tolerated in terms of undesirable side 
effects. This economic aspect should be considered as a 
selection criteria and taken into account for each patient 
(Palma, 2007).
The current study entailed a pharmacoeconomic 
analysis of the cost-benefit type, whose objective was 
to determine and compare the cost-effectiveness ratio 
of oxybutynin and tolterodine in their two formulations, 
namely capsules offering timed, controlled release (CR) 
and immediate release (IR), for the treatment of NDO. 
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The cost calculations in this study were based on the 2009 
maximum consumer price index compiled by the ANVISA 
for the year 2009, and patients’ perspective.
METHODOLOGY
A systematic literature review was done using the 
following databases: Pub Med, Cochrane Library, CI-
NAHL, Embase, MEDLINE, Web of Science, Current 
Controlled Trials, Evidence-NHS, Centre for Reviews and 
Dissemination (CRD York), INAHTA, LILACS, SciELO 
and IBECS. The review also included content from jour-
nals and those studies in the references of relevant articles 
which met the inclusion criteria. These searches were 
performed in each database by four independent reviewers.
No time limit was defined for publication date and 
only articles written in English and Spanish were included 
as no articles were found written in Portuguese. Retrieval 
was based on a total of 578 descriptive combinations 
including Bladder, Neurogenic; Cholinergic antagonists; 
Muscarinic Antagonists; Oxybutynin; Tolterodine and 
Urinary Bladder, Overactive.
The selected studies met the following inclusion 
criteria:
·	 Studies which included only NDO patients;
·	 Use of oxybutynin and tolterodine by oral route;
·	 Details given in the study on dose regimen/duration 
of treatment;
·	 Studies which used the two antimuscarinic agents, 
both prospective or retrospective;
·	 Inclusion of clinical and urodynamic information, 
showing effectiveness of the antimuscarinic therapy 
used.
The exclusion criteria applied were as follows:
·	 Integrated or narrative review articles, and
·	 Other antimuscarinic formulations used (intrablad-
der, transdermal).
A total of 29 studies were found meeting the inclu-
sion criteria, only 22 of which were included in the final 
sample for data extraction after evaluation. Among the 
principal reasons for exclusion of the initial 7 articles were 
the following problems: 
·	 Clinical and urodynamic parameters were not in-
dividually separated for each antimuscarinic drug 
studied, and 
·	 Absence of effectiveness parameters both pre and 
post treatment.
It is important to highlight that for a pharmacoeco-
nomic study, the average price paid by the consumer in the 
Brazilian market, was calculated (based on mean national 
price set by ANVISA in 2009) for the oral formulations 
(pills and capsules) of the two antimuscarinic drugs oxy-
butynin and tolterodine.
The following urodynamic parameters were used:
·	 Increase in cystometric capacity ≥ 10%;
·	 Decrease in detrusor pressure ≤ 40 cmH2O;
·	 Increase in bladder compliance.
The following clinical parameters were used:
·	 Increase in urinary volume eliminated in each uri-
nary effort or catheterization 
·	 Mean number of episodes of urgency with inconti-
nence and/or urge-incontinence.
Studies used to determine the efficacy of the medica-
tions in the pediatric population were: 1.Mahanta, K. et 
al. 2.Franco, I et al. 3.Cartwright, P. C. et al. 4.Goessl, C. 
et al. 5.Christoph, F. et al. 6.Reddy, P. P. et al. 7.Youdim, 
K. et al. 8.Madesbacher, H. et al. 9.Ferrara, P. et al. 10. 
Pannek, J. et al. 11.Ellsworth, P. I. et al. 11.Goessl, C. et al.
The selected studies which investigated the ef-
ficacy of these drugs in the adult population included: 
A.1.Bennett, N. et al. A.2.Kawabe, K. et al. A.3.Ethans, 
K. D. et al. A.4.Fader, M. et al. A.5.Horstmann, M. et 
al. A.6.Brooks, M. E. et al. A.7.Gajewski, J. B. et al. 
A.8.Stohrer, M. et al. A.9.Madersbacher, H. et al. A.10. 
Van Kerrebroeck, P. E. V. A. et al.
In order to calculate the daily, monthly and annual 
cost of each medication used, we calculated the average 
price according to the data available on pricing from the 
ANVISA site for 2009. In addition, it was necessary to 
calculate the weighted mean price of each pack of these 
antimuscarinic drugs, sold by all the pharmaceutical com-
panies which commercialize these products, according to 
the Tax on the Circulation of Goods and Services (ICMS) 
of each Brazilian State. The cost of each medication was 
then defined in terms of Reais per milligram (R$/mg).
The efficacy/effectiveness of the selected antimusca-
rinic drugs was stratified in terms of clinical and urodynamic 
parameters. Using values suggested by the literature search 
and a consensus opinion on this subject by specialists, the 
following urodynamic parameters of effectiveness after 
intervention were the following: a ≥10% increase in cys-
tometric capacity measured, detrusor pressure reduced to 
≤ 40 cmH2O, and augmented bladder compliance. In terms 
of the clinical parameters of effectiveness, the following 
were considered: increase in urinary volume excreted by 
natural means or by catheter, in a period of 24 hours, and a 
decrease in the average number of incontinence episodes 
(urgency or urge-incontinence) over a 24-hour period.
The most cost-effective medication was obtained 
by calculations based on monthly cost divided by the pa-
rameter measured in percentages and natural units. This 
method allowed calculation of the cost of a 1% increase or 
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decrease and one natural unit increase or decrease, for each 
investigated parameter. It is worth emphasizing that the 
average efficacy was calculated (along with the respective 
standard deviation) for all analyzed parameters, based on 
the average dose of each antimuscarinic drug, according to 
the doses adopted in the studies selected in the systematic 
literature search.
Precision of all calculations was to four decimal 
places. These were then reduced to two decimal places 
for ease of presentation of results.
RESULTS
The mean number of milligrams in each dose of 
the antimuscarinic studies and the corresponding average 
price is shown in Table I. The national average price of 
oxybutynin CR in 2009 was R$0.2295/mg and R$2.5472 
for tolterodine CR. The average price for IR oxybutynin 
was R$0.1269/mg versus R$ 2.0458 for IR Tolterodine.
Tables II and III give details regarding efficacy of 
each antimuscarinic drug, separately for pediatric and 
adult patients, according to the clinical data and urody-
namic parameters analyzed. 
It can be seen that tolterodine CR yielded better 
results than oxybutynin CR across all the urodynamic 
parameters evaluated, based on percentage values for both 
the pediatric and adult populations. For the IR formulation, 
tolterodine IR showed better performance in percentage 
terms than oxybutynin IR only for the increase in cysto-
metric capacity parameter in the pediatric population. For 
the rest of the parameters measured, in both pediatric and 
adult populations, oxybutynin gave better results com-
pared to tolterodine IR, suggesting it was more effective.
On clinical parameter analysis, the greatest volume 
increase in urinary volume eliminated with urination or 
by catheter use, was found with tolterodine CR, given the 
better percentage results obtained in comparison to oxy-
butynin CR. Comparing immediate release formulations 
(IR), tolterodine produced better results than oxybutynin 
in the pediatric group; but the reverse was true for the adult 
group in which oxybutynin had a superior result for the 
same parameter.
With regard to reduction in average number of 
incontinence episodes, tolterodine had better percentage 
results than oxybutynin only in the pediatric population 
and only for the IR formulation. No studies described this 
parameter for oxybutynin IR. Concerning the other popu-
lations and formulations, oxybutynin had the best results. 
Tables IV and V show daily dose in milligrams cal-
culated for each antimuscarinic drug, according to each 
selected study; the cost benefit ratio of each antimuscarinic 
drug is separated into urodynamic and clinical parameters 
respectively, considering the daily maintenance of the 
treatment over the time period considered.
The results suggest that Oxybutynin IR is the low-
est cost antimuscarinic medication offering the most 
favorable overall effectiveness in both pediatric and adult 
populations given its greater efficacy at a lower price for 
each urodynamic parameter studied. On the other hand, 
it should be noted that no reports investigating effective-
ness parameters for the outcome of reduction in detrusor 
pressure or increased bladder compliance, associated to 
the use of tolterodine CR were available.
In relation to the cost-effectiveness ratios for clinical 
parameters, the data suggest that oxybutynin IR is the low-
est cost antimuscarinic drug and has the lowest price asso-
ciated with a 1% increase in volume of urine eliminated by 
urination or catheter use. Considering the CR formulation 
in the adult population, information was available only for 
tolterodine whose cost was R$11.00.
In summary, regarding the parameter related to 
reduction in average number of urgency incontinence 
or urge-incontinence episodes, in the pediatric popula-
tion, the lowest cost and most effective muscarinic drug 
was oxybutynin in both CR and IR formulation. Studies 
were available only for tolterodine IR, whose cost was 
TABLE I - Average milligrams in antimuscarinic drug packs studied, according to average consumer price and price per milligram. 
Brazil, 2009
Antimuscarinic Drugs Amount per pack (mg) Average (SD) (mg)
APC* 
(R$)
Average Price 
(R$/mg)
Oxybutynin CR 300 300.00 (0.00) 68.86 R$ 0.2295
Oxybutynin IR 100 150 300 183.33 (84.98) 27.12 R$ 0.1269
Tolterodine CR            56        112 84.00 (28.00) 237.74 R$ 2.5472
Tolterodine IR 28 56 120 68.00 (38.51) 161.59 R$ 2.0458
(*) APC: Average price to consumer for 2009: Weighted average of all laboratories according to ICMS of each state, according 
to price list set by ANVISA for 2009.
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TABLE II - Urodynamic parameters of each antimuscarinic drug used in pediatric and adult populations, according to pre and post 
treatment data, and difference in each medication used. Brazil, 2009
Population Parameter
Antimuscarinic 
Drug
Study N
Mean Pre 
(SD)
Mean Post 
(SD)
Difference in 
unit values 
Difference 
in %
Pediatric
Cystometric 
capacity 
increased by 
≥10%
Oxy CR 2; 3 70 195.66 (2.90) 264.66 (9.71) +69.00 +35.27%
Tolt CR 1; 6; 11 64 159.16 (53.32) 225.32 (77.17) +66.16 +41.57%
Oxy IR 2; 3; 8; 9; 10; 12 248 186.86 (40.70) 267.82 (47.86) +80.96 +43.33%
Tolt IR 1; 4; 5; 6; 11 171 124.53 (6.93) 184.39 (88.14) +59.86 +48.07%
Detrusor 
pressure 
decreased 
≤40 cmH2O
Oxy CR 2;3 70 43.23 (0.77) 33.59 (0.26) -9.64 -22.30%
Tolt CR 1 25 50.00 (***) 36.80 (***) -13.20 -26.40%
Oxy IR 2; 3; 9; 12 135 46.22 (2.50) 30.18 (2.13) -16.04 -34.70%
Tolt IR 1; 4; 5 67 50.17 (12.76) 34.83 (1.97) -15.34 -30.58%
Bladder 
compliance 
improved
Oxy CR NR NR NR NR NR NR
Tolt CR 1 25 2.28 (***) 4.43 (***) +2.15 +94.30%
Oxy IR 9; 12 108 7.38 (0.80) 15.70 (1.00) +8.32 +112.74%
Tolt IR 1; 4; 5 90 10.86 (6.59) 12.37 (5.90) +1.51 +13.90%
Adult
Cystometric 
capacity 
increased by 
≥10%
Oxy CR NR NR NR NR NR NR
Tolt CR A.5 11 308.00 (***) 480.00 (***) +172.00 +55.84%
Oxy IR A.4; A.6; A.7; A.8; A.9 164 184.46 (32.26) 300.16 (28.20) +115.70 +62.72%
Tolt IR A.3; A.10 91 156.36 (39.26) 353.79 (205.81) +197.43 +126.27%
Bladder 
compliance 
increased
Oxy CR NR NR NR NR NR NR
Tolt CR NR NR NR NR NR NR
Oxy IR A.8; A.9 81 17.08 (4.93) 55.77 (20.22) +38.69 +226.52%
Tolt IR A.10 55 31.13 (13.70) 67.78 (6.90) +36.65 +117.73%
NR: data not reported in article.
*** Not possible to estimate standard deviation since only one article retrieved, and information was absent. Standard deviations were estimated 
as variation between means in articles, considering that each patient had a value equal to the corresponding weighted average. 
TABLE III - Clinical parameters for each antimuscarinic drug used in pediatric and adult populations, according to pre and post 
treatment data, and difference in each medication used. Brazil, 2009
Population Parameter
Antimuscarinic 
Drug
Study N
Mean Pre 
(SD)
Mean Post 
(SD)
Difference in 
unit values 
Difference 
in %
Pediatric
Increase in urinary 
volume eliminated 
by urination or 
catheterization
Oxy CR 2; 3 70 112.65 (57.23) 142.57 (72.95) +29.92 +26.56%
Tolt CR 6; 11 39 129.88 (4.79) 169.73 (7.70) +39.85 +30.68%
Oxy IR 2; 3 27 112.52 (0.43) 140.26 (7.42) +27. 4 +24.65%
Tolt IR 6; 11 123 57.20 (26.23) 73.78 (24.65) +16.58 +28.99%
Decreased number 
of episodes of U.I/ I 
in 24 hours
Oxy CR 7 12 8.50 (***) 1.80 (***) -6.70 -78.82%
Tolt CR 11 33 2.40 (000) 1.73 (0.29) -0.67 -27.92%
Oxy IR NR NR NR NR NR NR
Tolt L.IR 11 83 4.71 (0.45) 3.87 (0.52) -0.84 -17.83%
Adult
Increase in urinary 
volume eliminated 
by urination /
catheterization
Oxy CR NR NR NR NR NR NR
Tolt CR A.5 11 225.00 (***) 350.00 (***) +125. 0 +55.56%
Oxy IR A.2; A.8 54 179.80 (43.26) 215.42 (46.02) +35. 2 +19.81%
Tolt IR A.10 71 136.70 (5.85) 155.70 (11.87) +19.00 +13.90%
Decreased number 
of episodes of U.I/I 
in 24 hours
Oxy CR A.1 39 4.30 (***) 1.70 (***) -2.60 -60.47%
Tolt CR NR NR NR NR NR NR
Oxy IR A.4; A.7; A.8 121 2.33 (0.76) 1.28 (0,.6) -1.05 -45.06%
Tolt IR A.10 71 4.83 (1.19) 3.28 (0.90) -1.55 -32.09%
NR: data not reported in article.
*** Not possible to estimate standard deviation since only one article retrieved, and this information was absent. Standard deviations were 
estimated as variation between means found in articles, considering that each patient had a value equal to the corresponding weighted average.
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R$114.15 per episode avoided. For the adult population, 
the lowest cost per reduced episode was found to oxybu-
tynin in both IR and CR formulations, since no studies 
investigating the comparative costs for tolterodine CR 
were available.
DISCUSSION
The elevated costs of health management, especially 
those related to pharmaceutical costs to the patient have 
become a growing concern in public health. In the case 
of urology, and more specifically, among NDO patients, 
the costs involved in the diagnosis and treatment of this 
dysfunction can have a significant financial impact on 
patients and the health care system. One of the main 
reasons for this is the need for chronic use of medication 
and frequent medical consultations as well as exams such 
as urinary bacterial cultures, urodynamic examinations, 
ultrasonography as well as expenses with urinary catheters 
etc. In addition to these costs, indirect and intangible costs 
must also be considered such as impaired quality of life, 
caregiver burden (in cases of patients who cannot care 
for themselves) and loss of professional productivity in 
the work place.
Another aspect warranting emphasis regarding costs 
involved in NDO treatment is the lack of information on 
the average costs of treating NDO with pharmacologic 
agents. Nevertheless, in the case of bladder overactivity or 
idiopathic detrusor overactivity, medication costs represent 
a significant part of the direct treatment costs. In the United 
States, the cost of a year´s treatment with oxybutynin is 
$506 dollars while in the UK similar treatment costs £226 
a year. For tolterodine, the US costs are $1044 whereas in 
the UK the cost is £508 (McGhan, 2001).
The costs in Canada are estimated to be even higher. 
Direct and indirect costs of urinary incontinence in the 
TABLE IV - Cost-effectiveness ratios for urodynamic parameters according to % value and natural unit price, cost of therapy for 
one month and for one year, among pediatric and adult populations. Brazil, 2009
Population Parameter Antimuscarinic Drug
Average dose 
(mg/d)*
Increased Price 
[1%/(natural unit )]**
Price 
(1 month)***
Price 
(1 year)****
Pediatric
Cystometric 
capacity increased 
by ≥10%
Oxybutynin C.L 12.28 2.40/(1.22) 84.51 1014.16
Tolterodine C.L 3.28 6.02/(3.78) 250.26 3044.86
Oxybutynin I.R 8.99 0.77/(0.42) 34.14 415.33
Tolterodine I.R 2.02 2.58/(2.07) 123.80 1506.28
Detrusor pressure 
reduced 
≤40 cmH2O
Oxybutynin C.L 12.28 3.79/(8.77) 84.51 1014.16
Tolterodine C.L 2.00 5.79/(11.58) 152.83 1859.46
Oxybutynin I.R 4.72 0.51/(1.09) 17.97 218.64
Tolterodine I.R 2.88 5.28/(10.55) 176.57 2148.2
Bladder 
compliance 
increased
Oxybutynin C.L NR NR NR NR
Tolterodine C.L 2.00 1.62/(71.08) 152.83 1859.46
Oxybutynin I.R 3.09 0.11/(1.46) 11.77 143.15
Tolterodine I.R 2.71 11.98/(145.86) 166.09 2020.75
Adult
Cystometric 
Capacity increased 
by ≥10%
Oxybutynin C.L NR NR NR NR
Tolterodine C.L 8.00 10.95/(3.55) 611.33 7437.82
Oxybutynin I.R 13.26 0.81/(0.44) 50.49 614.30
Tolterodine I.R 3.66 4.80/(2.79) 224.75 2734.47
Bladder 
compliance 
increased
Oxybutynin C.L NR NR NR NR
Tolterodine C.L NR NR NR NR
Oxybutynin I.R 15.00 0.25/(1.44) 57.11 694.78
Tolterodine I.R 4.15 2.16/(6.94) 254.43 3095.53
NR: data not reported in article.
Price = in Reais (Brazil).
(*) Average daily dose in studies analyzed. (**) Additional R$ for every 1% increase or decrease in parameter, considering difference between 
post and pre intervention levels. (***)Considering one month as 30 days – price based on mean 2009 price. (****)Considering one year as 365 
days - price based on mean 2009 price. 
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TABLE V - Cost-effectiveness ratios for clinical parameters by % value and natural unit price, cost of therapy for one month and 
for one year, in both pediatric and adult populations. Brazil, 2009
Population Parameter
Antimuscarinic 
Drug
Average dose 
(mg/d)*
Price Increase 
[1%/(natural unit)]**
Price 
(1 month)***
Price 
(1 year)**** 
Pediatric
Increased Urinary 
volume eliminated/
catheterized
Oxybutynin CR 12.28 3.18/(2.82) 84.51 1014.16
Tolterodine CR 4.09 10.57/(8.14) 312.72 3804.72
Oxybutynin IR 11.24 1.74/(1.54) 42.78 520.45
Tolterodine IR 1.47 3.10/(5.43) 90.01 1095.07
Number of episodes 
of U.I 
or IU in 24 hours
Oxybutynin CR 8.88 1.04/(17.42) 61.12 743.58
Tolterodine CR 4.00 11.00/(458.47) 305.66 3718.91
Oxybutynin IR NR NR NR NR
Tolterodine IR 1.56 5.38/(114.15) 95.99 1167.85
Adult
Increased Urinary 
volume eliminated/
catheterized
Oxybutynin CR NR NR NR NR
Tolterodine CR 8.00 11.00/(4.89) 611.33 7437.82
Oxybutynin IR 14.50 3.02/(1.60) 55.20 671.62
Tolterodine IR 3.66 16.17/(11.83) 224.75 2734.47
Number of episodes 
of U.I 
or IU in 24 hours
Oxybutynin CR 19.49 2.22/(51.60) 134.17 1632.39
Tolterodine CR NR NR NR NR
Oxybutynin IR 12.64 1.07/(45.90) 48.14 585.68
Tolterodine IR 3.66 7.01/(145.20) 224.75 2734.47
NR: data not reported in article.
Price = in Reais ( Brazilian).
(*) Average daily dose in studies analyzed.  (**) Additional R$ for every 1% increase or decrease in parameter, considering difference between 
post and pre intervention levels. (***)Considering one month as 30 days – price based on mean 2009 price. (****)Considering one year as 365 
days – price based on mean 2009 price. 
Canadian population have been estimated at 2.6 billion 
dollars per year, which is higher than American costs. 
Considering each drug separately, a year of bladder over-
activity treatment with oxybutynin CR costs $656 (CAD), 
$534 of which is related directly to drug costs whereas 
$688 (CAD) represents the cost for a year’s treatment with 
tolterodine, of which $550 represents direct drug costs 
(Getsios, et al. 2004).
In the present study, the antimuscarinic drug with the 
best effectiveness profile and lowest price was oxybutynin. 
When stratifying by age group or pediatric/adult patients 
and both clinical and urodynamic parameters, oxybutynin 
remained the lowest cost with the best performance char-
acteristics.
In Brazil, weighted values for the antimuscarinic 
drug tolterodine are unfavorable, due to the economic 
conditions of the Brazilian population, in spite of the fact 
that tolterodine seems to be associated with better adher-
ence to therapy and to have a tolerability index three times 
higher than that of oxybutynin (McGhan, 2001).
Based on this assertion, tolterodine has become the 
second therapeutic option in clinical practice, indicated 
in oxybutynin-refractory cases. Another important aspect 
to be considered is that in Brazil, tolterodine is not yet 
included in the list of Medications Prescribable under Ex-
ceptional Circumstances (Componentes de Medicamentos 
de Dispensação Excepcional: CMDE), also called “high 
cost” drugs. This is important in that its use as a chronic 
ongoing therapy would be unaffordable for most of the 
Brazilian population.
The literature reinforces the fact that tolterodine is 
better accepted and tolerated. In a study involving Asian 
patients randomized to receive tolterodine (n=112) 2mg 
twice a day, or oxybutynin (n=116) 5 mg twice a day, 62 
of the 112 patients (55%) receiving tolterodine reported 
101 events involving side effects whereas 152 episodes of 
adverse effects were reported by 94 patients (82% ) in the 
oxybutynin group. Dry mouth was the most commonly 
reported side effect, followed by dyspepsia, abdominal 
pain, and headache (Lee et al. 2002). Another multi-
centric, double-blind, randomized study in which patients 
received either 2 mg of tolterodine (n=190) twice a day 
or 2.5 mg of oxybutynin (n=188) twice a day, in order 
to determine tolerability, showed that 22 (12%) of the 
tolterodine group dropped out of the study due to adverse 
effects, compared to 28 (15%) in the oxybutynin group. 
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Moreover, 132 (69%) patients complained of at least one 
side effect in the tolterodine group, in contrast to 153 un-
desirable similar side effects reported by the group of 188 
individuals on oxybutynin (81%). Dry mouth was once 
again the most commonly reported side effect found in 
71 out of 190 patients (37%) in the tolterodine group, and 
in 114 out of 188 patients (61%) in the oxybutynin group 
(Malone-Lee et al. 2001).
Our results suggest that the two antimuscarinic 
drugs, oxybutynin and tolterodine, show distinct outcomes 
as to their effectiveness. In the case of oxybutynin CR, this 
seems to be clinically relevant. This was especially notable 
in terms of the number of reduced episodes of incontinence 
(a highly significant clinical outcome measure for patient 
satisfaction). This resulted in an effectiveness of around 
60% for both population groups assessed. The pediatric 
population showed reduced incontinence episodes by an 
average of 6.7 episodes per day, while the adult group 
reported an average reduction in incontinence episode of 
2.6 per day. .
Analysis of the pertinent literature revealed an 
increasingly significant number of publications on the 
subject of bladder overactivity. However, studies ad-
dressing antimuscarinic treatment in the NDO patient 
population were scant and generally classified as based 
on a low quality of evidence. The major challenge in 
this area is to conduct studies with better methodological 
design, with a view to performing a meta-analysis on the 
resulting information. Thus, given the need for further 
studies on patients with NB, this preliminary exploratory 
study was of fundamental importance. Discovery of new 
technologies, especially low cost solutions, constitutes one 
of the most important factors for successful treatment of 
NDO, particularly with regard to the use of antimuscarinic 
medications.
CONCLUSION
This study found that in 2009, oxybutynin IR was the 
cheapest and most effective medication for the treatment 
of NDO, based on clinical and urodynamic parameters, in 
both the pediatric and adult populations in Brazil.
STUDY LIMITATIONS
This study was a pharmacoeconomic study using 
data from a systematic literature review, and thus cannot 
be considered a complete analysis of cost-effectiveness 
but instead a study of cost-consequence. The study aims 
were to present the incremental cost-effectiveness ratios 
for each clinical and urodynamic parameter considered, 
leaving the reader to decide which outcome is most im-
portant in their particular situation.
It is also important to emphasize that it was impos-
sible to obtain details regarding quality of life from the 
literature. This precluded the comparative study of other 
effectiveness parameters, such as years of life adjusted 
by quality, for the two alternative treatments from the 
perspective of one common denominator. 
Another noteworthy point is that this study did not 
employ rates of discount of future benefits and costs. The 
scope of this study was restricted to the costs related to 
the acquisition of the two medications studied, and for this 
reason the average ANVISA published prices to consum-
ers for 2009 was used.
In summary, this preliminary investigation paves 
the way for further research in this area. Broader studies 
should incorporate the results reported and could examine 
the incorporation of technologies, given the clear need for 
use of these drugs as part of the therapeutic arsenal for 
treatment of patients with chronic diseases such as NDO. 
The results of the present study should be interpreted with 
care for making health care decisions.
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